BRAF and neoplasm: The molecular basis of CPs has been elucidated with over 95% of pCP harbouring the BRAF c.1799T > A, p.(Val600Glu) variant commonly referred to as ‘V600E’ [3, 4], and this variant has recently been targeted with BRAF-MEK inhibitors with profound tumour shrinkage [5].